Infectious Diseases Institute, Makerere University
Kampala, Uganda
Location status: Recruiting
Location contact
Timothy Muwonge
CONTACT
NCT Number: NCT06126913
This is a cluster randomized controlled trial at 12 health centers in refugee settlements in Uganda aiming to evaluate effectiveness of expansion of community antiretroviral therapy (ART) delivery to people newly diagnosed with HIV in achieving HIV viral suppression.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
Kampala, Uganda
Location status: Recruiting
Timothy Muwonge
CONTACT
Community antiretroviral therapy (ART) delivery is a differentiated care model that fosters social support and reduces time and transportation barriers yielding improved engagement in HIV care. In Uganda, to participate in community ART delivery, clients must be "stable" in care (> 1 year on ART and viral load < 1,000 copies/mL). Therefore, persons newly diagnosed with HIV are not eligible for community ART delivery. Community ART delivery may benefit persons newly diagnosed with HIV in refugee settlements by bolstering social support and by bringing ART closer to individuals living in these expansive rural settlements. The primary objective of this research is to evaluate the effectiveness of expanding community ART delivery to clients newly diagnosed with HIV.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for data abstraction only:
Exclusion criteria
Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
Time frame: 12 months (+/- 2 months)
HIV viral suppression is defined as <1,000 copies/mL
Time frame: 6 months (+/- 2 months)
HIV viral suppression is defined as <1,000 copies/mL
Time frame: 12 months (+/- 2 months)
assessed by determining tenofovir diphosphate blood concentrations among those virally unsuppressed
Contact information is provided by the study sponsor or research team.
Kelli O'Laughlin, MD, MPH
CONTACT
Layla Anderson
CONTACT
University of Washington
Other
Achieving HIV Viral Suppression in Refugee Settlements in Uganda With Head StART: A Cluster Randomized Trial Evaluating the Effectiveness of Community ART Delivery for People Newly Diagnosed With HIV
Acronym: HeadStART
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05911360
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Phoenix, Arizona, United States
View Trial DetailsNCT05979311
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Ciudad Autonoma de Buenos Aire, Argentina
View Trial DetailsNCT06282328
AIDS, Acquired Immunodeficiency Syndrome
Milan, Italy
View Trial DetailsNCT06393387
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
West Palm Beach, Florida, United States
View Trial Details